Analysis of overall survival in sarcoma databases with respect to EMX1 and EMX2 levels suggest that, in general terms, a reduction in disease-free survival or/and overall survival was observed in the group of patients with low levels of EMX1 and EMX2 (Supplementary Fig. FS6). This evidence concerns the gene EMX2 and sarcoma.